PD-L1 antibodies and uses thereof
AssigneeSpring BioScience Corporation
InventorsFernando Jose Rebelo do Couto, Zhiming Liao, Yifei Zhu
Life of this patent
Estimating the term…
Abstract
Provided herein are PD-L1 antibodies and methods for using the same for diagnosing a medical condition associated with elevated PD-L1 levels (e.g., cancer) in subjects in need thereof and antigen binding fragments thereof. The PD-L1 antibodies and antigen binding fragments are also useful in evaluating the efficacy of a particular therapeutic regime in a subject diagnosed as having a PD-L1-related medical condition.
Claims12
An isolated antibody comprising a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the antibody specifically binds to an epitope of human PD-L1comprising the amino acid sequence CGIQDTNSKKQSDTHLEET (SEQ ID NO:
- 1) in formalin-fixed, paraffin embedded tissue with a half maximal effective concentration (EC50) of at least 1.5×10−11 M, wherein:
- the HC comprises
- (a) a HC CDR1 comprising the amino acid sequence NHAIS (SEQ ID NO:
- 14);
- and
- (b) a HC CDR2 comprising the amino acid sequence TINSDTHTYYATWPKG (SEQ ID NO:
- 15);
- and
- (c) a HC CDR3 comprising the amino acid sequence RIFSSSNI (SEQ ID NO:
- 16);
- and
- the LC comprises
- (a) a LC CDR1 comprising the amino acid sequence QASQSIYNNNWLS (SEQ ID NO:
- 17);
- and
- (b) a LC CDR2 comprising the amino acid sequence LASTLAS (SEQ ID NO:
- 12);
- and
- (c) a LC CDR3 comprising the amino acid sequence IGGESSNNDGIA (SEQ ID NO:
- 18);
- or an antigen binding fragment thereof.
Dependencies are inferred from the claim text.